A retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan/thiotepa for patients with central nervous system lymphomas at a single institution.
2/5 보강
TL;DR
The data suggest that Bu2TT had acceptable safety and efficacy and provide a rationale for further analyses in prospective multi-institutional trials.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
12 patients with CNSL who received Bu2TT (BU 3.
I · Intervention 중재 / 시술
Bu2TT (BU 3
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Our data suggest that Bu2TT had acceptable safety and efficacy. These results provide a rationale for further analyses in prospective multi-institutional trials.
OpenAlex 토픽 ·
CNS Lymphoma Diagnosis and Treatment
Lymphoma Diagnosis and Treatment
Glioma Diagnosis and Treatment
The data suggest that Bu2TT had acceptable safety and efficacy and provide a rationale for further analyses in prospective multi-institutional trials.
APA
Keiichiro Hattori, Naoki Kurita, et al. (2026). A retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan/thiotepa for patients with central nervous system lymphomas at a single institution.. International journal of hematology, 123(4), 593-599. https://doi.org/10.1007/s12185-025-04130-w
MLA
Keiichiro Hattori, et al.. "A retrospective analysis of autologous stem cell transplantation conditioning with reduced-dose busulfan/thiotepa for patients with central nervous system lymphomas at a single institution.." International journal of hematology, vol. 123, no. 4, 2026, pp. 593-599.
PMID
41400781 ↗
Abstract 한글 요약
[INTRODUCTION] Busulfan (BU)- and thiotepa (TT)-containing regimens have been approved for autologous stem cell transplantation (ASCT) in central nervous system lymphoma (CNSL). However, optimal doses of these regimens remain unclear. This study retrospectively analyzed the efficacy and toxicity of the Bu2TT regimen.
[METHOD] The study included 12 patients with CNSL who received Bu2TT (BU 3.2 mg/kg, days - 7 and - 6; TT 5 mg/kg, days - 5 and - 4) followed by ASCT at our institution after April 2020.
[RESULTS] Four patients were newly diagnosed (primary 3; secondary 1), and eight relapsed (primary 6; secondary 2). The median age was 62 years. Nine patients received high-dose MTX-based regimens as pre-transplant therapy. The other three received tirabrutinib, which was combined with localized radiotherapy (CyberKnife) in one patient. Disease status before ASCT was complete remission (CR) in 7 patients and partial remission in 5. Complications included febrile neutropenia (10/12 patients) and grade 3 anorexia (5/12 patients). Disease status after transplantation was CR in 10 patients and progressive disease in 2. OS and PFS rates at 2 years were 100% and 71%, respectively.
[CONCLUSION] Our data suggest that Bu2TT had acceptable safety and efficacy. These results provide a rationale for further analyses in prospective multi-institutional trials.
[METHOD] The study included 12 patients with CNSL who received Bu2TT (BU 3.2 mg/kg, days - 7 and - 6; TT 5 mg/kg, days - 5 and - 4) followed by ASCT at our institution after April 2020.
[RESULTS] Four patients were newly diagnosed (primary 3; secondary 1), and eight relapsed (primary 6; secondary 2). The median age was 62 years. Nine patients received high-dose MTX-based regimens as pre-transplant therapy. The other three received tirabrutinib, which was combined with localized radiotherapy (CyberKnife) in one patient. Disease status before ASCT was complete remission (CR) in 7 patients and partial remission in 5. Complications included febrile neutropenia (10/12 patients) and grade 3 anorexia (5/12 patients). Disease status after transplantation was CR in 10 patients and progressive disease in 2. OS and PFS rates at 2 years were 100% and 71%, respectively.
[CONCLUSION] Our data suggest that Bu2TT had acceptable safety and efficacy. These results provide a rationale for further analyses in prospective multi-institutional trials.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Thiotepa
- Busulfan
- Middle Aged
- Central Nervous System Neoplasms
- Retrospective Studies
- Male
- Female
- Transplantation Conditioning
- Aged
- Transplantation
- Autologous
- Hematopoietic Stem Cell Transplantation
- Lymphoma
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- Treatment Outcome
- Autologous stem cell transplantation
- Bu2TT
- Primary central nervous system lymphoma
- Secondary central nervous system lymphoma
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.